Literature DB >> 10904872

Characterization of a new animal model for human renal cell carcinoma.

K J Pulkkanen1, J J Parkkinen, M I Kettunen, R A Kauppinen, M Lappalainen, M Y Ala-Opas, S Yla-Herttuala.   

Abstract

BACKGROUND: Human renal cell carcinoma (RCC) is the most common kidney malignancy with significant mortality. Human tumor xenograft models are important tools for cancer research.
MATERIALS AND METHODS: We have established and characterized a new animal model for human RCC using Caki-2 cells implanted into the renal subcapsule (RSC) of nude mice. Histology, immunocytochemistry, in situ hybridization and magnetic resonance imaging (MRI) were used to analyze the tumors.
RESULTS: The implantations generated reproducible carcinomas which closely resemble human RCC. The tumors showed cystic-papillary structures, rich capillary network and fibro-septa formations. Proliferation varied from 0-5% and from 1-60% in cystic and solid areas, respectively. Apoptosis was less than 1%. Macrophages and other inflammatory cell infiltrations were detected in the tumors. VEGF-A and angiopoietin I were expressed in a small number of cells in large tumors. Tumors did not metastasize outside peritoneal cavity. Survival of the tumor bearing animals was 23 +/- 3 weeks.
CONCLUSIONS: It is concluded that Caki-2 carcinomas implanted into renal subcapsule of nude mice resemble human RCC in several aspects and represent a good animal model for studies regarding the pathogenesis and treatment of human RCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10904872

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  8 in total

1.  Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.

Authors:  Brendan D Looyenga; Kyle A Furge; Karl J Dykema; Julie Koeman; Pamela J Swiatek; Thomas J Giordano; Andrew B West; James H Resau; Bin T Teh; Jeffrey P MacKeigan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

2.  MRI detection of early bone metastases in b16 mouse melanoma models.

Authors:  Karen M Gauvain; Joel R Garbow; Sheng-Kwei Song; Angela C Hirbe; Katherine Weilbaecher
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 3.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

4.  Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma.

Authors:  Kylee A Rosette; Stephen M Lander; Calvin VanOpstall; Brendan D Looyenga
Journal:  Am J Physiol Renal Physiol       Date:  2021-05-24

Review 5.  Choosing the right cell line for renal cell cancer research.

Authors:  Klaudia K Brodaczewska; Cezary Szczylik; Michal Fiedorowicz; Camillo Porta; Anna M Czarnecka
Journal:  Mol Cancer       Date:  2016-12-19       Impact factor: 27.401

6.  Functional significance of CD105-positive cells in papillary renal cell carcinoma.

Authors:  Damian Matak; Klaudia K Brodaczewska; Cezary Szczylik; Irena Koch; Adam Myszczyszyn; Monika Lipiec; Slawomir Lewicki; Lukasz Szymanski; Robert Zdanowski; Anna M Czarnecka
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

7.  Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines.

Authors:  Damian Matak; Klaudia K Brodaczewska; Monika Lipiec; Łukasz Szymanski; Cezary Szczylik; Anna M Czarnecka
Journal:  Cytotechnology       Date:  2017-03-20       Impact factor: 2.058

8.  Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.

Authors:  Jörg Hänze; Moritz Wegner; Elfriede Noessner; Rainer Hofmann; Axel Hegele
Journal:  Target Oncol       Date:  2020-06       Impact factor: 4.493

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.